Cardiology
Study Keyword Search
ENDEAVOR III: A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Primary Investigator:
Angelo Ferraro, MD & Michael Ring, MD
Angelo Ferraro, MD & Michael Ring, MD
Description:
This study examines the safety and effectiveness of two different drug-eluting stents (ENDEAVOR and CYPHER stents) in patients with symptomatic heart disease. Participants will have single, untreated blockage(s) in one of their heart arteries as determined by coronary angiography. They will be randomized to receive either the ENDEAVOR stent (coated with ABT-578) or the CYPHER stent (coated with sirolimus). Participants will be followed for 5 years.
This study examines the safety and effectiveness of two different drug-eluting stents (ENDEAVOR and CYPHER stents) in patients with symptomatic heart disease. Participants will have single, untreated blockage(s) in one of their heart arteries as determined by coronary angiography. They will be randomized to receive either the ENDEAVOR stent (coated with ABT-578) or the CYPHER stent (coated with sirolimus). Participants will be followed for 5 years.
Eligibility:
- Age 18 years or older
- Have stable or unstable angina, silent ischemia or a positive functional study
- Meet angiographic criteria as determined by heart angiogram
- Other eligibility criteria may apply. Please contact study coordinator.
Exclusions:
- Unable to take aspirin or Plavix
- Other exclusion criteria may apply. Please contact study coordinator.
Study Timeline:
Closed to enrollment
Closed to enrollment
Study Sponsor:
Medtronic Vascular
Medtronic Vascular
Keywords :